Hansa Biopharma AB (publ)
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant pa… Read more
Market Cap & Net Worth: Hansa Biopharma AB (publ) (HNSBF)
Hansa Biopharma AB (publ) (PINK:HNSBF) has a market capitalization of $299.20 Million ($299.20 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #14612 globally and #5848 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hansa Biopharma AB (publ)'s stock price $3.00 by its total outstanding shares 99733953 (99.73 Million).
Hansa Biopharma AB (publ) Market Cap History: 2016 to 2025
Hansa Biopharma AB (publ)'s market capitalization history from 2016 to 2025. Data shows change from $1.38 Billion to $299.20 Million (-8.59% CAGR).
Hansa Biopharma AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hansa Biopharma AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.35x
Hansa Biopharma AB (publ)'s market cap is 1.35 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.38 Billion | $2.58 Million | -$111.13 Million | 533.28x | N/A |
| 2017 | $2.93 Billion | $3.44 Million | -$176.66 Million | 850.14x | N/A |
| 2018 | $3.16 Billion | $3.36 Million | -$247.97 Million | 941.50x | N/A |
| 2019 | $906.58 Million | $3.36 Million | -$360.01 Million | 269.50x | N/A |
| 2020 | $2.94 Billion | $6.10 Million | -$420.85 Million | 482.48x | N/A |
| 2021 | $1.01 Billion | $33.88 Million | -$548.28 Million | 29.73x | N/A |
| 2022 | $491.69 Million | $154.53 Million | -$611.13 Million | 3.18x | N/A |
| 2023 | $225.10 Million | $134.09 Million | -$831.72 Million | 1.68x | N/A |
| 2024 | $364.03 Million | $171.32 Million | -$806.74 Million | 2.12x | N/A |
| 2025 | $299.20 Million | $222.26 Million | -$529.25 Million | 1.35x | N/A |
Competitor Companies of HNSBF by Market Capitalization
Companies near Hansa Biopharma AB (publ) in the global market cap rankings as of March 19, 2026.
Key companies related to Hansa Biopharma AB (publ) by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Hansa Biopharma AB (publ) Historical Marketcap From 2016 to 2025
Between 2016 and today, Hansa Biopharma AB (publ)'s market cap moved from $1.38 Billion to $ 299.20 Million, with a yearly change of -8.59%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $299.20 Million | -17.81% |
| 2024 | $364.03 Million | +61.72% |
| 2023 | $225.10 Million | -54.22% |
| 2022 | $491.69 Million | -51.19% |
| 2021 | $1.01 Billion | -65.76% |
| 2020 | $2.94 Billion | +224.53% |
| 2019 | $906.58 Million | -71.32% |
| 2018 | $3.16 Billion | +8.04% |
| 2017 | $2.93 Billion | +112.76% |
| 2016 | $1.38 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Hansa Biopharma AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $299.20 Million USD |
| MoneyControl | $299.20 Million USD |
| MarketWatch | $299.20 Million USD |
| marketcap.company | $299.20 Million USD |
| Reuters | $299.20 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.